**Obesity Platforms Go Beyond the Scale, AI Takes the Wheel**

Picture this: yesterday's biotech buzz flipped the script on fat loss drugs from quick fixes to full blown platforms that rethink metabolism, while AI stops hyping discovery and starts calling real shots in trials. Deals explode as big players chase next gen assets, cell therapies hit scaling walls, and China muscles in like never before. It's a wild pivot year where software could glue it all together, turning clunky labs into prediction machines that outsmart biology itself.

Obesity's Platform Revolution
Obesity treatments hit a platform era, blending GLP1s with amylin for smarter weight loss that spares muscle and tackles root causes, not just pounds. Supply chains scramble to match demand, but the real game changer lurks in software overlays that model patient responses in real time, predicting who thrives on combo therapies before a single dose. Why settle for blunt instruments when algorithms could personalize metabolic resets, challenging the one size-fits-all pill push?

AI Ditches Hype for Trial Room Power
AI evolves from discovery toy to development boss, slashing cycle times, refining protocols, stratifying patients, and even picking sites with eerie precision. Companies like Insilico push AI born drugs into midstage trials, boasting 40 to 50 percent faster timelines and higher success rates. Nvidia teams with Lilly on supercomputing labs scream potential, yet imagine agentic AI workflows that autonomously tweak experiments. Does this finally crack the 90 percent failure rate, or just automate expensive flops?

Cell Gene Therapies Face Scale Reckoning
CGT boasts clinical wins but chokes on operations, with replication at scale and routine use still pipe dreams. Watch for reproducible manufacturing and surgery flows that hold up long term. Here software shines ruthless: digital twins simulating cell factories could blueprint industrial ramps, exposing weak links before billions vanish. Will biotech industrialize or stay boutique forever?

M&A Frenzy Targets Platforms and Pipelines
Mergers surge on patent cliffs, obesity next gens, ADCs dominating 40 percent of antibody deals, and China's pipeline allure. Buyers crave vertical control over manufacturing and platforms, paying premiums for differentiated assets in RNA, bispecifics, and large market bets like Alzheimer's. Software vision: AI driven deal simulators forecasting post merger synergies, spotting overpays in bloated valuations. Tension brews as optimism clashes with regulatory wild cards; who blinks first in this acquisition arms race?

China and Modalities Reshape the Board
China claims 20 percent of global pipelines, fueling M&A while modalities like RNAi for hearts and one shot genes target roots. Big pharma doubles down on durable immunology and inflammation plays. Provocative angle: open source software platforms could democratize these tools, letting startups leapfrog giants. But geopolitics loom; can Western code outpace Eastern scale without compromise?